This site took a lengthy hiatus after Covid struck leaving our tables of ‘Upcoming’ and ‘Recent’ Spinoffs quite stale. I am sure this has been quite the disappointment to our readers and we do hate to disappoint! As we slowly turn the engines back on here, we will try to clean up the tables and fill in the… Read More »
Grab your cup of coffee and kick off the week with some Odds and Ends: Late last year, Pfizer (PFE) announced it was considering its ‘options’ for its consumer health division. The early buzz was all about a sale though and the maker of Advil and Centrum has since been running a sales process with a rumored desired… Read More »
Way back in 2013, Pfizer (PFE) CEO Ian Read plotted a future course that could have included a spinoff several years down the line. Since then there have been constant rumors and speculations about possible breakups and portfolio changes, but those were ultimately rejected. Last week though, the company shifted gears by formally announcing that it is considering its… Read More »
BioGen (BIIB) has finally chosen a name for its upcoming hemophilia drug focused spinoff. The new company will be called Bioverativ and it will eventually trade on the Nasdaq under the ticker ‘BIVV’. Bioverativ will be a global biotech company ‘focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders.’ It’s growing… Read More »
M&A gets a lot of attention, but many have questioned whether or not it delivers the expected returns to shareholders. Often this is a result of paying too much. While the data on spinoffs is pretty favorable (we might be a bit biased here), the transaction can have some consequences. For example, if the parent company doesn’t retain… Read More »